

UC Davis

UC Davis Previously Published Works

Title

Genetic Ablation of Butyrate Utilization Attenuates Gastrointestinal Salmonella Disease

Permalink

<https://escholarship.org/uc/item/2hx7r95h>

Journal

Cell Host & Microbe, 23(2)

ISSN

1931-3128

Authors

Bronner, Denise N
Faber, Franziska
Olsan, Erin E
[et al.](#)

Publication Date

2018-02-01

DOI

10.1016/j.chom.2018.01.004

Peer reviewed



HHS Public Access

Author manuscript

Cell Host Microbe. Author manuscript; available in PMC 2019 February 14.

Published in final edited form as:

Cell Host Microbe. 2018 February 14; 23(2): 266–273.e4. doi:10.1016/j.chom.2018.01.004.

Genetic ablation of butyrate utilization attenuates gastrointestinal *Salmonella* disease

Denise N. Bronner¹, Franziska Faber^{1,2}, Erin E. Olsan¹, Mariana X. Byndloss¹, Nada A. Sayed¹, Gege Xu³, Woongjae Yoo¹, Dajeong Kim⁴, Sangryeol Ryu^{4,5}, Carlito B. Lebrilla³, and Andreas J. Bäuml^{1,6,*}

¹Department of Medical Microbiology and Immunology, School of Medicine, University of California at Davis, One Shields Avenue, Davis, CA 95616, USA

²Current address: Department of Molecular Infection Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany

³Department of Chemistry, College of Letters and Sciences, University of California at Davis, One Shields Avenue, Davis, CA 95616, USA

⁴Department of Food and Animal Biotechnology, Department of Agricultural Biotechnology, Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul 08826, Republic of Korea

⁵Center for Food and Bioconvergence, Seoul National University, Seoul 08826, Republic of Korea

⁶Lead Contact

SUMMARY

Salmonella enterica serovar (*S.*) Typhi is an extraintestinal pathogen that evolved from *Salmonella* serovars causing gastrointestinal disease. Compared to non-typhoidal *Salmonella* serovars, the genomes of typhoidal serovars contain various loss-of-function mutations. However, the contribution of these genetic differences to this shift in pathogen ecology remains unknown. We show that the *ydiQRSTD* operon, which is deleted in *S.* Typhi, enables *S.* Typhimurium to utilize microbiota-derived butyrate during gastrointestinal disease. Unexpectedly, genetic ablation of butyrate utilization reduces *S.* Typhimurium epithelial invasion and attenuates intestinal inflammation. Deletion of *ydiD* renders *S.* Typhimurium sensitive to butyrate-mediated repression of invasion gene expression. Combined with the gain of virulence-associated (Vi) capsular polysaccharide and loss of very-long O antigen chains, two features characteristic of *S.* Typhi,

*Correspondence: ajbauml@ucdavis.edu.

AUTHOR CONTRIBUTIONS

Conceptualization, D.N.B., F.F., and A.J.B. Methodology, D.N.B., F.F., E.E.O., and A.J.B.; Investigation, D.N.B., F.F., E.E.O., M.X.B., N.A.S., G.X., W.Y., and D.K.; Resources, S.R., C.B.L., and A.J.B. Funding Acquisition, E.E.O. and A.J.B.; Writing – Original Draft, D.N.B. and A.J.B.; Writing – Review & Editing, D.N.B. and A.J.B.; Supervision, S.R., C.B.L., and A.J.B.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

DECLARATION OF INTERESTS

The authors declare no competing interests.

genetic ablation of butyrate utilization abrogates *S. Typhimurium*-induced intestinal inflammation. Thus, the transition from a gastrointestinal to extraintestinal pathogen involved discrete genetic changes, providing insights into pathogen evolution and emergence.

Graphical Abstract



eTOC blurb

Bronner et al. show that genes enabling *Salmonella enterica* serovar (*S.*) Typhimurium to utilize microbiota-derived butyrate are deleted in the genome of the closely related *S. Typhi*, thereby moderating intestinal inflammation induced by the pathogen. Thus, gene loss can aid in the transition from gastrointestinal to extraintestinal pathogens.

INTRODUCTION

From the standpoint of human disease, the genus *Salmonella* is traditionally divided into zoonotic non-typhoidal *Salmonella* serovars and human-adapted typhoidal *Salmonella* serovars. After an incubation period of less than 24 hours, non-typhoidal *Salmonella* serovars cause a localized gastrointestinal disease in patients with an intact immune system (Glynn and Palmer, 1992). In contrast, typhoidal *Salmonella* serovars cause an extraintestinal disease after an average incubation period of two weeks (Olsen et al., 2003). This extraintestinal disease is referred to as typhoid fever, when associated with *Salmonella enterica* serovar (*S.*) Typhi, or as paratyphoid fever, when caused by *S. Paratyphi A* (Crump et al., 2004; Kirk et al., 2015). The long incubation period of typhoid fever suggests that unlike non-typhoidal *Salmonella* serovars, *S. Typhi* limits severe intestinal inflammation early after infection. One genetic factor implicated in moderating intestinal inflammation during typhoid fever is the virulence-associated (Vi) capsular polysaccharide, which was acquired by *S. Typhi* through horizontal gene transfer of the *viaB* locus (Haneda et al., 2009; Wilson et al., 2008; Wilson et al., 2011). However, the *viaB* locus is not present in *S.*

Paratyphi A, suggesting that additional genetic changes curbing a rapid onset of intestinal inflammation remain to be identified in typhoidal *Salmonella* serovars.

A virulence factor crucial for inducing severe intestinal inflammation during infection with the non-typhoidal *S. Typhimurium* is the invasion-associated type III secretion system (T3SS-1) (Tsolis et al., 1999). Expression of genes encoding T3SS-1 can be modulated by short-chain fatty acids (SCFAs) both *in vitro* and in the gastrointestinal tract (Garner et al., 2009; Lawhon et al., 2002). SCFAs are fermentation end products of the gut microbiota that can trigger acid stress responses as well as modulate virulence factor expression in enteric pathogens (Altier, 2005). Butyrate and propionate have been shown to reduce expression of *Salmonella* invasion genes, whereas acetate enhances invasion gene expression (Gantois et al., 2006; Lawhon et al., 2002). Mixtures representing colonic SCFA concentrations, which contain higher proportions of butyrate and propionate, exhibit a greater inhibitory effect than mixtures representing ileal SCFA concentrations, which contain a higher proportion of acetate (Altier, 2005). Since typhoidal and non-typhoidal *Salmonella* serovars encounter similar SCFA concentrations during infection, this regulatory mechanism is not a likely candidate for explaining why only the latter pathogens cause severe intestinal inflammation after an incubation period of less than 24 hours.

An overt genetic difference between typhoidal and non-typhoidal *Salmonella* serovars is the presence in the former genomes of significantly larger numbers of loss-of-function mutations (McClelland et al., 2004; Parkhill et al., 2001). The majority of functions lost by deletion or gene disruption (pseudogene formation) in genomes of typhoidal *Salmonella* serovars are involved in central anaerobic metabolism, which is required for expansion of non-typhoidal *Salmonella* serovars in the gut lumen during gastrointestinal disease (Nuccio and Baumler, 2014). However, in many cases the predicted functions of metabolic pathways lost in typhoidal *Salmonella* serovars remain to be established experimentally using an animal model. For example, both the *S. Typhi* and *S. Paratyphi A* genomes carry a deletion of the *ydiQRSTD* operon, but this deletion is not present in other *Salmonella* genomes (Nuccio and Baumler, 2014). Sequence homology predicts that the *S. Typhimurium* *ydiQRSTD* operon encodes a pathway for β -oxidation of fatty acids in the presence of nitrate (Campbell et al., 2003), an electron acceptor becoming available in the intestinal lumen during gastrointestinal disease (Lopez et al., 2015; Lopez et al., 2012). This predicted role suggests *S. Typhi* and *S. Paratyphi A* lost the *ydiQRSTD* operon because they do not cause gastrointestinal disease and hence no longer need metabolic pathways that enhance bacterial growth in the inflamed intestine. Here we characterize the role of the *ydiQRSTD* operon during infection to illuminate its role in the evolutionary path from a gastrointestinal to an extraintestinal pathogen.

RESULTS

***S. Typhimurium* utilizes microbiota-derived butyrate using anaerobic β -oxidation**

To investigate whether the anaerobic pathway for β -oxidation of fatty acids conferred a fitness advantage during growth in the intestinal lumen, we compared the fitness of the *S. Typhimurium* wild type (IR715) and a *ydiD* mutant (DNB4) by infecting genetically resistant (CBA) mice with a 1:1 mixture of both strains. The *S. Typhimurium* wild type was

recovered in significantly higher numbers ($P < 0.001$) from colon contents than the *ydiD* mutant (Fig. 1A), suggesting that anaerobic β -oxidation conferred a fitness advantage during pathogen growth in the lumen. Interestingly, in germ-free (Swiss Webster) mice, wild type and *ydiD* mutant were recovered in similar numbers from colon contents; however, when pre-colonized with a community of 17 human *Clostridia* isolates, anaerobic β -oxidation conferred a significant fitness advantage ($P < 0.001$) (Fig. 1B). *Clostridia* are the main producers in gut-associated microbial communities of the SCFA butyrate (Louis and Flint, 2009; Vital et al., 2014). When germ-free mice infected with a 1:1 mixture of the *S. Typhimurium* wild type and a *ydiD* mutant received butyrate supplementation, anaerobic β -oxidation conferred a significant fitness advantage ($P < 0.01$) (Fig. 1B). The finding that deletion of *ydiD* generated a phenotype in germ-free mice only after supplementation with *Clostridia* or with butyrate supported the idea that the anaerobic β -oxidation pathway is required *in vivo* for utilization of microbiota-derived butyrate, but not for utilization of host or diet derived fatty acids. Consistent with the idea that the anaerobic β -oxidation pathway is required for butyrate utilization, the *S. Typhimurium* wild type consumed butyrate under anaerobic conditions *in vitro*, while butyrate consumption was not observed with a *ydiD* mutant (Fig. 1C). Butyrate consumption *in vitro* could be restored in a *ydiD* mutant by introducing the cloned *ydiD* gene on a plasmid (pYDID).

Genetic ablation of butyrate utilization attenuates the severity of colitis

Next, we wanted to further characterize the *ydiD* mutant by infecting mice with individual bacterial strains. In genetically resistant (CBA) mice, *S. Typhimurium* causes severe colitis within 10 days after infection, as indicated by measuring the inflammatory marker lipocalin-2 in feces by ELISA (Rivera-Chavez et al., 2016). Remarkably, deletion of *ydiD* attenuated the ability of *S. Typhimurium* to trigger intestinal inflammation, as indicated by significantly ($P < 0.0001$) lower lipocalin-2 levels in feces of CBA mice infected with a *ydiD* mutant compared to mice infected with *S. Typhimurium* wild type (Fig. 2A). This result was unexpected, because genetic ablation of other metabolic pathways required for bacterial growth in the intestinal lumen, such as ethanolamine utilization (Thiennimitt et al., 2011) or nitrate respiration (Lopez et al., 2015), does not moderate intestinal inflammation. Introducing the cloned *ydiD* gene on a plasmid (pYDID) restored fecal lipocalin-2 levels elicited by the *ydiD* mutant to levels observed in the *S. Typhimurium* wild type, suggesting that the effect was not due to unlinked mutations. Similarly, analysis of histopathological changes revealed that a *ydiD* mutant caused significantly reduced intestinal inflammation compared to the *S. Typhimurium* wild type or a complemented *ydiD* mutant (Fig. 2B). Transcript levels of *Il17a* and *Kc*, encoding two cytokines (IL-17A and KC) involved in neutrophil recruitment, were significantly ($P < 0.0001$) higher in cecal tissue of mice infected with the *S. Typhimurium* wild type or complemented *ydiD* mutant compared to mice infected with a *ydiD* mutant (Fig. 2C). T3SS-1-mediated neutrophil recruitment into the intestinal lumen is associated with a depletion of *Clostridia* from the gut-associated microbial community (Gill et al., 2012; Sekirov et al., 2010). Quantification of *Clostridia* by real-time PCR using class-specific primers revealed that the abundance of this taxon in the gut-associated microbial community was markedly reduced in mice infected with *S. Typhimurium* wild type or the complemented *ydiD* mutant compared to mice infected with a *ydiD* mutant (Fig. 2D), which correlated with reduced cecal butyrate concentrations (Fig.

2E). These data suggested that, surprisingly, genetic ablation of butyrate utilization markedly blunted the severity of intestinal inflammation during *S. Typhimurium* infection.

Butyrate utilization is essential for robust T3SS-1 gene expression and epithelial invasion

Next, we wanted to determine the mechanism by which deletion of *ydiD* attenuated gastrointestinal disease. Anaerobic growth of the *ydiD* mutant was impaired in the presence of 3 mM butyrate, but not in the absence of butyrate (Fig. S1A and S1B). However, this growth defect alone was not a likely explanation for attenuated gastrointestinal disease, because reduced bacterial growth *in vivo* caused by genetic ablation of ethanolamine utilization or nitrate respiration does not moderate intestinal inflammation (Lopez et al., 2015; Thiennimitr et al., 2011). A functional T3SS-1 is required for gastrointestinal disease caused by *S. Typhimurium* in calves (Tsolis et al., 1999) and for eliciting colitis in mice (Barthel et al., 2003). Butyrate inhibits expression of *hilD*, encoding a positive regulator of T3SS-1 gene expression, through an unknown mechanism (Gantois et al., 2006). Since *S. Typhi* lacks the anaerobic β -oxidation pathway encoded by *ydiQRSTD*, we explored whether *S. Typhi* would exhibit reduced invasion gene expression in the presence of butyrate. No differences in expression of *invA*, encoding a component of the T3SS-1 apparatus, were observed between *S. Typhi* and *S. Typhimurium* when bacteria were cultured anaerobically in the presence of acetate (Fig. S1C). However, in the presence of 3 mM butyrate (mimicking butyrate levels encountered in the small intestine), transcript levels of *invA* were significantly lower in *S. Typhi* and in a *S. Typhimurium ydiD* mutant compared to the *S. Typhimurium* wild type (Fig. 3A). While *S. Typhi*, *S. Typhimurium* and a *S. Typhimurium ydiD* mutant were equally invasive for T84 cells in a standard gentamicin protection assay, invasion of *S. Typhi* and the *S. Typhimurium ydiD* mutant was significantly reduced compared to the *S. Typhimurium* wild type when the assay was performed under hypoxic (0.8% O₂) conditions with SCFA concentrations resembling those in the small intestine (12 mM acetate, 5 mM propionate and 3 mM butyrate) (Fig. 3B).

Butyrate utilization maintains T3SS-1 gene expression in the small intestine

Seeing that *invA* expression was repressed in the *ydiD* mutant, we explored whether *hilD* gene expression and invasion efficacy were defective in the presence of SCFAs *in vitro*. Anaerobic growth in medium mimicking SCFA levels encountered in the small intestine (12 mM acetate, 5 mM propionate, and 3 mM butyrate) resulted in significantly ($P < 0.0001$) reduced expression of *hilD* in a *ydiD* mutant compared to the *S. Typhimurium* wild type (Fig. 3C). Introducing the cloned *ydiD* gene on a plasmid (pYDID) restored invasion gene expression in the *ydiD* mutant in the presence of SCFAs. When grown in the presence of 12 mM acetate, no significant differences in *invA* or *hilD* gene expression were observed between the *S. Typhimurium* wild type, a *ydiD* mutant or the complemented *ydiD* mutant (Fig. S2A). However, supplementation with 3 mM butyrate significantly ($P < 0.0001$) reduced *invA* and *hilD* expression in the *ydiD* mutant when compared to wild type or the complemented *ydiD* mutant (Fig. S2B). The results of an electrophoretic mobility shift assay (EMSA) suggested that reduced *hilD* expression was not caused by butyrate inhibiting HilD to bind its own promoter (Fig. S2C).

Next, we investigated whether inactivation of butyrate utilization would reduce bacterial invasion of Peyer's patches in the small intestine *in vivo*. To monitor invasion in the absence of microbiota-derived SCFAs, germ-free mice were infected intragastrically with the *S. Typhimurium* wild type, a *ydiD* mutant or the complemented *ydiD* mutant, ileal Peyer's patches were collected one hour later and treated with gentamicin to kill extracellular bacteria. No differences in invasiveness between bacterial strains were observed in the absence of butyrate; however, when germ-free mice received drinking water supplemented with butyrate, the *ydiD* mutant was recovered in significantly ($P < 0.0001$) lower numbers from Peyer's patches than the wild type or the complemented *ydiD* mutant (Fig. 3D).

Finally, we examined the importance of butyrate utilization for invasion gene expression and Peyer's patch invasion in the presence of a normal gut microbiota. The *invA* and *hilD* genes were expressed in significantly lower levels in the cecal contents of CBA mice three days after infection with the *ydiD* mutant compared to mice infected with *S. Typhimurium* wild type (Fig. 3E). As a control, we determined expression of *ssrA*, a positive regulator of the second *S. Typhimurium* type III secretion system (T3SS-2), which remained unchanged in the *S. Typhimurium* wild type compared to a *ydiD* mutant (Fig. 3E). Recovery of gentamicin-resistant bacteria from Peyer's patches revealed that the *ydiD* mutant was significantly ($P < 0.0001$) less invasive in mice with a normal microbiota than the wild type or the complemented *ydiD* mutant (Fig. 3F). Collectively, these data suggested that genetic ablation of butyrate utilization rendered *S. Typhimurium* more sensitive to a butyrate-mediated repression of T3SS-1 invasion gene expression, thereby diminishing epithelial invasion.

Three genetic changes in *S. Typhi* cooperate to moderate gastrointestinal disease

Two genetic changes have been implicated in moderating intestinal inflammation during typhoid fever. One is the *viaB* locus, a DNA region containing genes for the synthesis of the virulence-associated (Vi) capsular polysaccharide, which was acquired by *S. Typhi* through horizontal gene transfer (Haneda et al., 2009; Wilson et al., 2008; Wilson et al., 2011). Introduction of the *S. Typhi* *viaB* locus into *S. Typhimurium* enhances proliferation of the pathogen at extraintestinal sites, such as the spleen (Jansen et al., 2011) and moderates the severity of intestinal inflammation in a mouse model (Haneda et al., 2009). The second genetic change is a loss-of-function mutation in *fepE*, encoding the length regulator of very-long O-antigen chains (Crawford et al., 2013). Since the *ydiQRSTD* operon is absent in *S. Typhi*, we wanted to investigate whether genetic ablation of *ydiD* could further reduce intestinal inflammation caused by a *S. Typhimurium* *phoN::viaB fepE* mutant.

One hour after intragastric infection of CBA mice, both the *S. Typhimurium* *phoN::viaB fepE* mutant and *S. Typhimurium* *ydiD* mutant exhibited significantly reduced invasion of Peyer's patches compared to *S. Typhimurium* wild type (Fig. 4A). Importantly, the *S. Typhimurium* *phoN::viaB fepE ydiD* mutant was recovered in significantly lower numbers than either of the aforementioned strains (Fig. 4A). Fecal lipocalin-2 levels were significantly lower 10 days after infection of mice with a *S. Typhimurium* *phoN::viaB fepE ydiD* mutant compared to mice infected with a *S. Typhimurium* *phoN::viaB fepE* mutant or a *S. Typhimurium* *ydiD* mutant (Fig. 4B). Furthermore, inflammatory changes induced by

infection with *S. Typhimurium* wild type were significantly reduced in mice infected with either a *S. Typhimurium* *phoN::viaB fepE* mutant or a *S. Typhimurium ydiD* mutant. Importantly, inflammation was abrogated in mice infected with a *S. Typhimurium phoN::viaB fepE ydiD* mutant (Fig. 4C). These data suggested that deletion of *ydiD* cooperates with inactivation of *fepE* and acquisition of *viaB* in moderating intestinal inflammation during typhoid fever. Bacterial recovery from systemic sites (spleen and liver) suggested that enhanced dissemination to or survival in extraintestinal tissue was mediated mainly by the *phoN::viaB fepE* mutations (Fig. 4D and S3A–S3C). Collectively, our data suggests just three genetic changes in *S. Typhi* cooperated to moderate intestinal inflammation during the initial stages of typhoid fever. Interestingly, two of these genetic changes, formation of a pseudogene (*fepE*) and a chromosomal deletion (*ydiQRSTD*), are loss-of-function mutations.

DISCUSSION

Generally, loss-of-function mutations reduce bacterial fitness. Contrary, our results suggest that deletion of *ydiQRSTD* bestowed the ability upon *S. Typhi* and *S. Paratyphi A* to moderate intestinal inflammation (Fig. 2). Acquisition of the *viaB* locus and pseudogene formation in *fepE* further decreased intestinal inflammation (Crawford et al., 2013; Haneda et al., 2009), while increasing dissemination to and/or survival in the liver and spleen (Fig. 4D), by enabling *S. Typhi* to avert the phagocyte respiratory burst (Miller et al., 1972). *S. Paratyphi A*, a typhoidal *Salmonella* serovar lacking the *viaB* locus, acquired the ability to avert the respiratory burst of phagocytes through pseudogene formation in *rfbE*, an example of convergent evolution (Hiyoshi et al., 2018). The result was a gain-of-function leading to the transition from a gastrointestinal to an extraintestinal infection profile. The idea that deletion of *ydiQRSTD* was involved in the transition from a gastrointestinal to an extraintestinal pathogen is further supported by previous genome comparisons. The most parsimonious explanation for the presence of a *ydiQRSTD* deletion in both *S. Typhi* and *S. Paratyphi A*, but not in genomes of non-typhoidal *Salmonella* serovars, is horizontal exchange of this DNA region between typhoidal *Salmonella* serovars. This is consistent with observations made by genome comparison, which suggests that *S. Typhi* exchanged a remarkable 23% of its genome with *S. Paratyphi A* through horizontal gene transfer, an event that is postulated to mark the origin of typhoid and paratyphoid fever (Didelot et al., 2007; Holt et al., 2008). Our results suggest that this horizontal transfer event included exchange of the *ydiQRSTD* deletion between *S. Typhi* and *S. Paratyphi A*, which resulted in a moderation of intestinal inflammation, a characteristic that distinguishes typhoidal from non-typhoidal *Salmonella* serovars.

Subsequent to this large-scale horizontal exchange, the *S. Typhi* and *S. Paratyphi A* lineages began to accumulate loss-of-function mutations at an accelerated rate, a process that is still in progress (Holt et al., 2008). Many pseudogenes acquired during the phase of accelerated genomic decay resulted in loss of pathways involved in central anaerobic metabolism, which are required for expansion of non-typhoidal *Salmonella* serovars, such as *S. Typhimurium*, in the gut lumen during gastrointestinal disease (Nuccio and Baumler, 2014). Our results support a model in which accelerated genome decay was preceded by acquisition of genetic changes (i.e. a deletion of *ydiQRSTD*, acquisition of *viaB* and pseudogen formation in *fepE*)

that moderated intestinal inflammation (Fig. 5), suggesting that this phenotypic change was an evolutionary driver of accelerated genome decay in typhoidal *Salmonella* serovars, because it made functions obsolete that are only needed for taking advantage of intestinal inflammation.

STAR METHODS

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Andreas J. Bäumlér (ajbaumlér@ucdavis.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Bacterial strains and culture conditions.—The 17 human Clostridia isolates were kindly provided by K. Honda (Atarashi et al., 2011; Narushima et al., 2014) and were cultured individually as described previously (Atarashi et al., 2013). Unless indicated otherwise, *S. Typhimurium* and *E. coli* strains (Key Resources Table) were routinely grown aerobically at 37°C in LB broth (BD Biosciences, cat. # 244620) or on LB agar plates. If appropriate, antibiotics were added to the media at the following concentrations: 0.03 mg/ml chloramphenicol, 0.1 mg/ml carbenicillin, 0.05 mg/ml kanamycin, and 0.05 mg/ml nalidixic acid. For growth under anaerobic conditions, reduced rich broth (tryptone, 10 g/L, NaCl, 5 g/L, and yeast extract 1 g/L, 0.1M MOPS pH 7.8, 40 mM sodium fumarate) was inoculated with the indicated strain and incubated at 37°C in an anaero be chamber (0% oxygen). When necessary SCFAs were added at a concentration of 20 mM (12 mM acetate, 5 mM propionate, and 3 mM butyrate). Six hours after inoculation, cultures were harvested and stored at –80°C for subsequent RNA extraction.

Cell Culture Systems.—The colonic carcinoma cell line T84 was obtained from the American Type Culture Collection. T84 cells were routinely maintained in DMEM-F12 medium (1.2 g/l sodium bicarbonate, 2.5 mM L-glutamine, 15 mM HEPES, 0.5 mM sodium pyruvate (Invitrogen), and 10% fetal bovine serum (FBS; Invitrogen).

Animal Experiments.—All experiments in this study were approved by the Institutional Animal Care and Use Committee at the University of California at Davis. Female CBA mice, aged 8 weeks, were obtained from The Jackson Laboratory. Germ-free Swiss-Webster mice were bred in house. Mice were housed in ventilated cage racks on corn bedding, providing water and mouse chow *ad libidum*. Mice were monitored twice daily and cage bedding changed every two weeks.

CBA mice were infected with either 0.1 ml of LB broth (mock-infected) or *S. Typhimurium* in LB broth. For single infections, mice were inoculated with 1×10^9 CFU of the indicated *S. Typhimurium* strains. Peyer's patches were collected 1 hour after infection for quantifying *Salmonella* invasion. To assess intestinal inflammation, mice were euthanized at 10 days after infection, cecal contents, colon contents, spleen, and liver were collected for enumeration of bacterial numbers and the proximal colon and cecal tip were collected for

histopathology. Bacterial numbers were determined by plating serial ten-fold dilutions onto LB agar containing the appropriate antibiotics.

For competitive infections, conventional mice were inoculated with 1×10^9 CFU of a 1:1 mixture of the indicated strains. *Salmonella*-infected germ-free mice were inoculated with 17 human *Clostridia* isolates by oral gavage or given 150 mM sodium butyrate in the drinking water then inoculated with 1×10^9 CFU of a 1:1 mixture of the indicated strains. Fecal pellets were collected at the indicated time points to monitor colonization over time.

METHOD DETAILS

Invasion assay.—T84 cells were seeded 2.5×10^5 cells/well and infected with indicated strains at a multiplicity of infection (MOI) of 10. The bacteria and cells were exposed to hypoxic conditions in a humidified hypoxia chamber (0.8% O₂, Coy Laboratory products) while being incubated for 1 h at 37°C in DMEM-F12 medium containing 20 mM SCFA mix (12 mM acetate, 5 mM propionate, and 3 mM butyrate) during invasion. Each well was washed three times with sterile PBS (KCl at 2.7 mM, KH₂PO₄ at 1.8 mM, NaCl at 140 mM, Na₂HPO₄ at 10 mM, pH 7.4) to remove extracellular bacteria, and medium containing gentamicin at a concentration of 0.1 mg/ml was added for a 90-min incubation in conditions stated above. After three washes with PBS, the cells were lysed with 1 ml of 1% Triton X-100 and the lysates were transferred to sterile tubes. Tenfold serial dilutions were plated to enumerate intracellular bacteria.

ELISA assay.—Colon contents were used to assess lipocalin-2 levels. Lipocalin-2 levels were determined by sandwich enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions. A minimum of 6 biological replicates were used for each experimental group.

Quantitative real-time PCR analysis.—After euthanasia for murine RNA isolation, cecal tissue sections were homogenized in a Mini-Beadbeater (BioSpec Products, Bartlesville, OK) and RNA was isolated by the TRI-Reagent method following the manufacturer's protocol. Contaminating DNA was removed using the DNA-free kit and RNA was stored at -80°C.

To determine invasion gene expression during *in vitro* growth in the presence of SCFA, RNA from frozen bacterial pellets was extracted using the Aurum Total RNA mini Kit (BioRad, cat. #: 7326820). DNA remaining in the RNA isolation portion was removed using the DNA-free kit (Applied Biosystems, cat. #: AM1906). Target gene transcription was normalized to the levels of β -actin mRNA for murine gene expression. Target gene transcription was normalized to the levels of *S. Typhimurium* 16S rRNA gene mRNA for bacterial gene expression. As a control, bacterial target gene expression was normalized to the *S. Typhimurium rpoA* gene message, which produced similar results as normalization with the 16S rRNA gene message (data not shown). Fold change in mRNA levels was determined using the comparative threshold cycle (C_T) method and conditions were compared to either *S. Typhimurium* or *S. Typhi* in the absence of SCFAs for bacterial gene expression (*invA*, *hilD*) or mock-infected cecal tissue for murine gene expression experiments (*III7a*, *Kc*).

DNA from the cecal contents was extracted using the PowerSoil DNA Isolation kit according to the manufacturer's protocol. PCR mix and the appropriate primer sets (Supplementary table 1) at a final concentration of 0.25 mM. Absolute values were calculated using a plasmid carrying the cloned gene to generate a standard curve ranging from 10^8 to 10^1 copies/ml diluted in a 0.02 mg/ml yeast RNA (Sigma-Aldrich, cat. # R6750) solution.

Construction of *Salmonella* Typhimurium mutants.—All strains, plasmids and primers used in this study are listed in Supplementary tables 1 or the Key Resources Table. PCR products were confirmed by sequencing. The suicide plasmid pRDH10 was propagated in *E. coli* DH5a λ pir.

To generate a *ydiD* mutant, regions upstream and downstream of *ydiD* were PCR amplified from the *S. Typhimurium* wild-type strain IR715 using primers *ydiD*-P1,2,3 and 4 (Supplementary table 1). The PCR fragments were gel purified and cloned into BamHI digested pRDH10 using Gibson Assembly Master Mix (NEB) yielding plasmid pXY. Plasmid pXY was conjugated into *S. Typhimurium* IR715 (wild type) and AJB715 (*phoN*::Km^R) using *E. coli* S17-1 λ pir as a donor strain. Exconjugants were plated onto LB +Nal+Cm to select for clones that had integrated the suicide plasmid. Sucrose counter-selection was performed as published previously (Lawes and Maloy, 1995). Strains that were sucrose resistant and Cm^S were verified by PCR to carry the *ydiD* deletion. The resulting *ydiD* mutants were designated FF357 (*ydiD*) and DNB4 (*phoN*::Km^R *ydiD*).

To generate the *fepE*::pGP704 *phoN*::*viaB ydiD* mutant, *fepE*::pGP704 and *phoN*::*viaB* were subsequently transduced into FF357 (*ydiD*) by generalized P22 HT *int-105* phage transduction using strain RC60 as donor strain. Transductants were cleaned from phage contaminations on Evans blue-Uranine (EBU) plates and tested for phage sensitivity by crossstreaking against P22 H5.

For complementation of FF357, the *ydiD* gene together with its native promoter region was PCR amplified using primers *ydiDc*-P1, P2, P3 and P4. The PCR fragments were gel purified and cloned into BamHI digested pWSK29 using Gibson Assembly Master Mix (NEB). The resulting plasmid (pYDID) was transformed into strain FF357 for complementation.

Plasmid construction.—For the construction of pWJ19 producing His₆-HilD (HilD protein tagged with six histidines at its N-terminus) under T7 promoter, the DNA containing the *Salmonella* Typhimurium 14028s *hilD* gene was amplified by PCR using primers of HilD-His-F and HilD-His-R, and the PCR products were introduced between NdeI and EcoRI sites of pET28a (Novagen, cat. # 69864).

Expression and purification of His₆-HilD.—*E. coli* BL21 (DE3) (Novagen, 69450) containing pWJ19 expressing His₆-HilD was grown in 100 ml of LB media at 37°C in a shaken incubator at 220 rpm. At an optical density of 0.5, the expression of His₆-HilD was induced by adding 1 mM isopropyl- β -D-thiogalactopyranoside and the bacterial culture was allowed to grow for another 16 hours at 18°C in a shaken incubator at 180 rpm. The His₆-

HilD proteins were purified using nikel-nitrilotriacetic acid (Ni-NTA) resin (Qiagen, cat. # 30410) according to the manufacturer's instructions, and the bound proteins were eluted with elution buffer [20 mM Tris-HCl (pH 8.0), 300 mM NaCl, and 250 mM imidazole]. The eluted proteins were concentrated by using a VivaSpin 20 instrument (3,000-molecular-weight cutoff [MWCO] polyethersulfone; GE Healthcare, 28-9323-58), and the elution buffer was replaced with storage buffer [20 mM Tris-HCl (pH 8.0), 300 mM NaCl, and 50% glycerol] using a PD MidiTrap G-25 column (GE Healthcare, 28-9180-08). Protein concentration was determined using the Bradford assay with BSA as the standard.

EMSA.—EMSA experiments were performed as described previously (Campbell et al., 2008; Martinez et al., 2014). DNA fragments containing the *hilD* promoter (the -130/+75 region of *hilD*) were amplified by PCR using primers hilD-EMSA-F and hilD-EMSA-R with wild-type *Salmonella* Typhimurium 14028s chromosomal DNA as a template. The amplified PCR products were purified from agarose gels using a gel extraction kit (Qiagen, cat. # 28706). Binding reactions were performed by mixing 0.8 pmol of PCR products with increasing concentrations of purified His₆-HilD in binding buffer containing 10 mM Tris-HCl (pH 8.0), 0.5 mM EDTA (pH 8.0), 1 mM DTT, 50 mM KCl, 10 µg/ml BSA, and 10 µg/ml Poly dI-dC, in a total volume of 20 µl. Protein-DNA binding reaction mixtures were incubated at room temperature for 30 minutes and then electrophoretically separated in 6% nondenaturing poly-acrylamide gels in 0.5X Tris-borate-EDTA buffer. The DNA fragments were stained by using EMSA Kit according to the manufacturer's instructions and visualized with a Gel Doc™ EZ (Bio-Rad, cat. # 1708270).

Measurements of short-chain fatty acid concentrations.—Samples of cecal and colon contents were diluted with nanopore water (10 µl/mg) and gently agitated overnight at 4°C. The homogenized samples were centrifuged at 21,000 × g for 5 min. 100 µl of the supernatants were transferred centrifuged at 21,000 × g again for 20 min. For each sample, 20 µl of the supernatant was mixed with 20 µl of 100 mM N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1-EDC HCl) (Sigma-Aldrich, cat. # E7750) in 5% pyridine (Sigma-Aldrich cat. # 270407) and 40 µl of 200 mM 2-Nitrophenylhydrazine (2-NPH) (Sigma-Aldrich, cat. # N21588) in 80% acetonitrile (ACN) (Sigma-Aldrich, cat. # BJAH015-4) with 50 mM HCl. The mixture was incubated at 40°C for 30 min. After reacting, 420 µl of 10% ACN was added to the solution. Then 1 µl the solution was injected into an Agilent 6490 triple quadruple mass spectrometer for analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS

All data are expressed as the mean and standard error of the mean. Group sizes of animals were determined by power calculation. The number of animals (n) for each group is provided in the figure legends. Ratios were converted logarithmically prior to statistical analysis to ensure data are normally distributed. A Student's *t*-test was used for statistical analyses of all measurements. A *P* value of < 0.05 was considered significant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

E.E.O. was supported by Public Health Service Grant TR001861 (E.E.O.). Work in A.J.B.'s laboratory is supported by Public Health Service Grants AI044170, AI096528, AI112445 and AI112949.

REFERENCES

- Altier C (2005). Genetic and environmental control of salmonella invasion. *J Microbiol* 43 *Spec No*, 85–92. [PubMed: 15765061]
- Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, et al. (2013). Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature* 500, 232–236. [PubMed: 23842501]
- Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, et al. (2011). Induction of colonic regulatory T cells by indigenous Clostridium species. *Science* 331, 337–341. [PubMed: 21205640]
- Barthel M, Hapfelmeier S, Quintanilla-Martinez L, Kremer M, Rohde M, Hogardt M, Pfeffer K, Russmann H, and Hardt WD (2003). Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. *Infect Immun* 71, 2839–2858. [PubMed: 12704158]
- Campbell JW, Morgan-Kiss RM, and Cronan JE, Jr. (2003). A new Escherichia coli metabolic competency: growth on fatty acids by a novel anaerobic beta-oxidation pathway. *Mol Microbiol* 47, 793–805. [PubMed: 12535077]
- Campbell LA, Faivre EJ, Show MD, Ingraham JG, Flinders J, Gross JD, and Ingraham HA (2008). Decreased recognition of SUMO-sensitive target genes following modification of SF-1 (NR5A1). *Mol Cell Biol* 28, 7476–7486. [PubMed: 18838537]
- Crawford RW, Wangdi T, Spees AM, Xavier MN, Tsohis RM, and Baumler AJ (2013). Loss of very-long O-antigen chains optimizes capsule-mediated immune evasion by Salmonella enterica serovar Typhi. *mBio* 4.
- Crump JA, Luby SP, and Mintz ED (2004). The global burden of typhoid fever. *Bulletin of the World Health Organization* 82, 346–353. [PubMed: 15298225]
- Didelot X, Achtman M, Parkhill J, Thomson NR, and Falush D (2007). A bimodal pattern of relatedness between the Salmonella Paratyphi A and Typhi genomes: convergence or divergence by homologous recombination? *Genome research* 17, 61–68. [PubMed: 17090663]
- Faber F, Tran L, Byndloss MX, Lopez CA, Velazquez EM, Kerrinnes T, Nuccio SP, Wangdi T, Fiehn O, Tsohis RM, et al. (2016). Host-mediated sugar oxidation promotes postantibiotic pathogen expansion. *Nature* 534, 697–699. [PubMed: 27309805]
- Gantois I, Ducatelle R, Pasmans F, Haesebrouck F, Hautefort I, Thompson A, Hinton JC, and Van Immerseel F (2006). Butyrate specifically down-regulates salmonella pathogenicity island 1 gene expression. *Appl Environ Microbiol* 72, 946–949. [PubMed: 16391141]
- Garner CD, Antonopoulos DA, Wagner B, Duhamel GE, Keresztes I, Ross DA, Young VB, and Altier C (2009). Perturbation of the small intestine microbial ecology by streptomycin alters pathology in a Salmonella enterica serovar typhimurium murine model of infection. *Infect Immun* 77, 2691–2702. [PubMed: 19433544]
- Gill N, Ferreira RB, Antunes LC, Willing BP, Sekirov I, Al-Zahrani F, Hartmann M, and Finlay BB (2012). Neutrophil elastase alters the murine gut microbiota resulting in enhanced Salmonella colonization. *PLoS one* 7, e49646. [PubMed: 23155475]
- Glynn JR, and Palmer SR (1992). Incubation period, severity of disease, and infecting dose: evidence from a Salmonella outbreak. *Am J Epidemiol* 136, 1369–1377. [PubMed: 1488963]
- Haneda T, Winter SE, Butler BP, Wilson RP, Tukel C, Winter MG, Godinez I, Tsohis RM, and Baumler AJ (2009). The capsule-encoding *viaB* locus reduces intestinal inflammation by a Salmonella pathogenicity island 1-independent mechanism. *Infect Immun* 77, 2932–2942. [PubMed: 19451244]

- Hiyoshi H, Wangdi T, Lock G, Saechao C, Raffatellu M, Cobb BA, and Bäumler AJ (2018). Mechanisms to evade the phagocyte respiratory burst arose by convergent evolution in typhoidal *Salmonella* serovars. *Cell Reports*, In press.
- Holt KE, Parkhill J, Mazzoni CJ, Roumagnac P, Weill FX, Goodhead I, Rance R, Baker S, Maskell DJ, Wain J, et al. (2008). High-throughput sequencing provides insights into genome variation and evolution in *Salmonella* Typhi. *Nature genetics* 40, 987–993. [PubMed: 18660809]
- Jansen AM, Hall LJ, Clare S, Goulding D, Holt KE, Grant AJ, Mastroeni P, Dougan G, and Kingsley RA (2011). A *Salmonella* Typhimurium-Typhi Genomic Chimera: A Model to Study Vi Polysaccharide Capsule Function In Vivo. *PLoS Pathog* 7, e1002131. [PubMed: 21829346]
- Kingsley RA, Humphries AD, Weening EH, De Zoete MR, Winter S, Papaconstantinou P, Dougan G, and Baumler AJ (2003). Molecular and phenotypic analysis of the CS54 island of *Salmonella enterica* serotype typhimurium: identification of intestinal colonization and persistence determinants. *Infect Immun* 71, 629–640. [PubMed: 12540539]
- Kingsley RA, Reissbrodt R, Rabsch W, Ketley JM, Tsolis RM, Everest P, Dougan G, Baumler AJ, Roberts M, and Williams PH (1999). Ferrioxamine-mediated Iron(III) utilization by *Salmonella enterica*. *Appl Environ Microbiol* 65, 1610–1618. [PubMed: 10103258]
- Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleeschauwer B, Dopfer D, Fazil A, Fischer-Walker CL, Hald T, et al. (2015). World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data Synthesis. *PLoS Med* 12, e1001921. [PubMed: 26633831]
- Lawes M, and Maloy S (1995). MudS*acI*, a transposon with strong selectable and counterselectable markers: use for rapid mapping of chromosomal mutations in *Salmonella typhimurium*. *J Bacteriol* 177, 1383–1387. [PubMed: 7868615]
- Lawhon SD, Maurer R, Suyemoto M, and Altier C (2002). Intestinal short-chain fatty acids alter *Salmonella typhimurium* invasion gene expression and virulence through BarA/SirA. *Mol Microbiol* 46, 1451–1464. [PubMed: 12453229]
- Lopez CA, Rivera-Chavez F, Byndloss MX, and Baumler AJ (2015). The Periplasmic Nitrate Reductase NapABC Supports Luminal Growth of *Salmonella enterica* Serovar Typhimurium during Colitis. *Infect Immun* 83, 3470–3478. [PubMed: 26099579]
- Lopez CA, Winter SE, Rivera-Chavez F, Xavier MN, Poon V, Nuccio SP, Tsolis RM, and Baumler AJ (2012). Phage-mediated acquisition of a type III secreted effector protein boosts growth of salmonella by nitrate respiration. *mBio* 3.
- Louis P, and Flint HJ (2009). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS microbiology letters* 294, 1–8. [PubMed: 19222573]
- Martinez LC, Banda MM, Fernandez-Mora M, Santana FJ, and Bustamante VH (2014). HilD induces expression of *Salmonella* pathogenicity island 2 genes by displacing the global negative regulator H-NS from *ssrAB*. *J Bacteriol* 196, 3746–3755. [PubMed: 25135218]
- McClelland M, Sanderson KE, Clifton SW, Latreille P, Porwollik S, Sabo A, Meyer R, Bieri T, Ozersky P, McLellan M, et al. (2004). Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of *Salmonella enterica* that cause typhoid. *Nat Genet* 36, 1268–1274. [PubMed: 15531882]
- Miller RM, Garbus J, and Hornick RB (1972). Lack of enhanced oxygen consumption by polymorphonuclear leukocytes on phagocytosis of virulent *Salmonella typhi*. *Science* 175, 1010–1011. [PubMed: 5009393]
- Narushima S, Sugiura Y, Oshima K, Atarashi K, Hattori M, Suematsu M, and Honda K (2014). Characterization of the 17 strains of regulatory T cell-inducing human-derived *Clostridia*. *Gut microbes* 5, 333–339. [PubMed: 24642476]
- Nuccio SP, and Baumler AJ (2014). Comparative analysis of *Salmonella* genomes identifies a metabolic network for escalating growth in the inflamed gut. *mBio* 5, e00929–00914. [PubMed: 24643865]
- Olsen SJ, Bleasdale SC, Magnano AR, Landrigan C, Holland BH, Tauxe RV, Mintz ED, and Luby S (2003). Outbreaks of typhoid fever in the United States, 1960–99. *Epidemiol Infect* 130, 13–21. [PubMed: 12613741]

- Pal D, Venkova-Canova T, Srivastava P, and Chatteraj DK (2005). Multipartite regulation of rctB, the replication initiator gene of *Vibrio cholerae* chromosome II. *J Bacteriol* 187, 7167–7175. [PubMed: 16237000]
- Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, Churcher C, Mungall KL, Bentley SD, Holden MT, et al. (2001). Complete genome sequence of a multiple drug resistant *Salmonella enterica* serovar Typhi CT18. *Nature* 413, 848–852. [PubMed: 11677608]
- Rivera-Chavez F, Zhang LF, Faber F, Lopez CA, Byndloss MX, Olsan EE, Xu G, Velazquez EM, Lebrilla CB, Winter SE, et al. (2016). Depletion of Butyrate-Producing Clostridia from the Gut Microbiota Drives an Aerobic Luminal Expansion of *Salmonella*. *Cell Host Microbe* 19, 443–454. [PubMed: 27078066]
- Sekirov I, Gill N, Jogova M, Tam N, Robertson M, de Llanos R, Li Y, and Finlay BB (2010). *Salmonella* SPI-1-mediated neutrophil recruitment during enteric colitis is associated with reduction and alteration in intestinal microbiota. *Gut microbes* 1, 30–41. [PubMed: 21327114]
- Simon R, Priefer U, and Puhler A (1983). A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram-negative bacteria. *Bio/Technology* 1, 784–791.
- Stojiljkovic I, Baumler AJ, and Heffron F (1995). Ethanolamine utilization in *Salmonella typhimurium*: nucleotide sequence, protein expression, and mutational analysis of the cchA cchB eutE eutJ eutG eutH gene cluster. *J Bacteriol* 177, 1357–1366. [PubMed: 7868611]
- Studier FW, and Moffatt BA (1986). Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. *J Mol Biol* 189, 113–130. [PubMed: 3537305]
- Thiennimitr P, Winter SE, Winter MG, Xavier MN, Tolstikov V, Huseby DL, Sterzenbach T, Tsolis RM, Roth JR, and Baumler AJ (2011). Intestinal inflammation allows *Salmonella* to utilize ethanolamine to compete with the microbiota. *Proc Natl Acad Sci U S A*, In press.
- Tsolis RM, Adams LG, Ficht TA, and Baumler AJ (1999). Contribution of *Salmonella typhimurium* virulence factors to diarrheal disease in calves. *Infect Immun* 67, 4879–4885. [PubMed: 10456944]
- Vital M, Howe AC, and Tiedje JM (2014). Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. *mBio* 5, e00889. [PubMed: 24757212]
- Wang RF, and Kushner SR (1991). Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in *Escherichia coli*. *Gene* 100, 195–199. [PubMed: 2055470]
- Wilson RP, Raffatellu M, Chessa D, Winter SE, Tukel C, and Baumler AJ (2008). The Vi-capsule prevents Toll-like receptor 4 recognition of *Salmonella*. *Cell Microbiol* 10, 876–890. [PubMed: 18034866]
- Wilson RP, Winter SE, Spees AM, Winter MG, Nishimori JH, Sanchez JF, Nuccio SP, Crawford RW, Tukel C, and Baumler AJ (2011). The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of *Salmonella enterica* serotype Typhi. *Infection and immunity* 79, 830–837. [PubMed: 21098104]

Highlights

Anaerobic β -oxidation enables *S. Typhimurium* to utilize microbiota-derived butyrate

Loss of anaerobic β -oxidation renders invasion gene expression sensitive to butyrate

S. Typhi gained the ability to moderate inflammation by losing anaerobic β -oxidation

Gene loss drove the transition from a gastrointestinal to an extraintestinal pathogen




Figure 1: *S. Typhimurium* uses anaerobic β -oxidation to utilize microbiota-derived butyrate. (A) CBA mice ($n = 6$) were intragastrically infected with an equal mixture of *S. Typhimurium* IR715 wild type (WT) and a *ydiD* mutant. The competitive Index (CI) was determined on days 1, 3, 10, and 17 after infection (p.i.) in fecal and colon contents. (B) Swiss-Webster germ-free mice ($n = 6$) were mock treated, supplemented with 17 human *Clostridia* isolates or with butyrate (150 mM in drinking water) and then infected intragastrically with a 1:1 mixture of the *S. Typhimurium* wild type (WT) and a *ydiD* mutant. (C) Medium containing 3mM butyrate was inoculated with the indicated bacterial strains, incubated anaerobically for 8 hours and butyrate concentrations were measured using liquid chromatography-mass spectrometry. Error bars represent geometric mean \pm SE. *, ** and *** represents p-value <0.01 , 0.001 and <0.0001 , respectively.




Figure 2: Genetic ablation of anaerobic β -oxidation moderates intestinal inflammation.

(A) Lipocalin-2 levels were determined by ELISA in colon contents of mice 10 days after infection with the indicated *S. Typhimurium* IR715 strains. (B) Histopathological changes were scored in blinded sections of the cecum. Each bar represents the combined scoring results for one individual animal. (C) Expression levels of *Il17a* mRNA and *Kc* mRNA isolated from the cecal tissue 10 days after infection in CBA mice. Transcript levels were normalized to actin levels and are shown as fold-change over transcript levels in mock-infected animals. (D) *Clostridia* 16S rRNA gene copy numbers present in 20 ng of total bacterial DNA were determined at 10 days post infection in CBA mice infected with the indicated *S. Typhimurium* strains. (E) The butyrate concentration was determined in cecal contents using liquid chromatography-mass spectrometry 10 days after infection of mice with the indicated *S. Typhimurium* strains. For (A – D) each circle and square represents data from an individual animal. *** represents p-value <0.0001, n.s. = not significant.




Figure 3: Genetic ablation of anaerobic β -oxidation decreases invasion in the presence of SCFAs. (A) *S. Typhimurium* wild type (WT), a *S. Typhimurium ydiD* mutant, and *S. Typhi* strain Ty2 were grown under anaerobic conditions in rich broth supplemented with the indicated concentrations of butyrate. Transcript levels of *invA* were quantified by real-time polymerase chain reaction (PCR), normalized to 16S ribosomal RNA (rRNA) levels and shown as fold-change over transcript levels detected in medium without SCFA supplementation. (B) T84 cells were infected for 1 hour with the indicated bacterial strains under hypoxic conditions (0.8% O₂). Bacterial numbers were recovered after 90 minutes of gentamicin treatment (n = 3). (C) The *S. Typhimurium* IR715 wild type (WT), a *ydiD* mutant, and a complemented *ydiD* mutant (*ydiD* pYDID) were grown under anaerobic conditions in rich broth supplemented with 20 mM SCFAs (12 mM acetate, 5 mM propionate, and 3 mM butyrate) and bacterial RNA was collected. (D) Swiss-Webster gnotobiotic mice (n = 6) were infected with the *S. Typhimurium* IR715 wild type, a *ydiD* mutant, or a complemented *ydiD* mutant (10⁹ CFU). To measure invasion, mice were euthanized one hour after infection to enumerate intracellular bacteria in Peyer's patches.

(E) Bacterial RNA was isolated from colon contents of *S. Typhimurium*-infected mice. (C and E) Transcript levels of *invA*, *hilD*, and *ssrA* were quantified by real-time polymerase chain reaction (PCR), normalized to 16S ribosomal RNA (rRNA) levels and shown as fold-change over transcript levels detected in medium without SCFA supplementation. (F) CBA mice (n = 6) were infected as described in (D). Error bars in (A-C) represent mean \pm SD of n = 3 independent experiments. For (B – D) each circle and square represents data from an individual animal. ** and *** represents p-values <0.001 and <0.0001, n.s. = not significant.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4: Deletion of *ydiD* cooperates with acquisition of *viaB* and pseudogene formation in *fepE* to moderate intestinal inflammation.

(A) CBA mice (n = 6) were infected with the *S. Typhimurium* IR715 wild type (WT), a *ydiD* mutant, a *fepE* *phoN::viaB* mutant or a *fepE* *phoN::viaB* *ydiD* mutant. To measure invasion, mice were euthanized one hour after infection and Peyer's patches collected to enumerate intracellular bacteria. (B) Lipocalin-2 levels were determined by ELISA from colon contents in mice infected with the indicated *S. Typhimurium* strains 10 days after infection. (C) Histopathological changes were scored in blinded sections of the cecum. Each bar represents the combined scoring results for one individual animal. (D) Spleen CFU of *S. Typhimurium*

in CBA mice (n = 6) 10 days after infection. For (A – C) each circle represents data from an individual animal. *, **, and *** represents p-values <0.01, <0.001, and <0.0001.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Key Resources Table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bacterial and Virus Strains		
Ty2	<i>S. Typhi</i> isolate, Vi ⁺	ATCC 19430
IR715	Nalidixic acid-resistant derivative of ATCC 14028s	(Stojiljkovic et al., 1995)
FF176	IR715 <i>phoN::Tn10d-Cam</i>	(Faber et al., 2016)
AJB715	IR715 <i>phoN::Km^R</i>	(Kingsley et al., 2003)
FF357	IR715 <i>ydiD</i>	This study
DNB4	IR715 <i>phoN::Km^R ydiD</i>	This study
RC60	IR715 <i>phoN::viaB fepE::pGP704</i>	(Crawford et al., 2013)
DNB3	IR715 <i>phoN::viaB fepE::pGP704 ydiD</i>	This study
<i>Salmonella</i> Typhi Ty2	ATCC	ATCC 19430
<i>Salmonella</i> Typhimurium IR715	Nalidixic acid-resistant derivative of ATCC 14028s	(Stojiljkovic et al., 1995)
DH5α <i>λpir</i>	F ⁻ <i>endA1 hsdR17(γ-m⁺) supE44 thi-1 recA1 gyrA relA1 (lacZYA-argF)_{U189} φ80lac M15 λpir</i>	(Pal et al., 2005)
S17-1 <i>λpir</i>	C600::RP4 2-(Tet::Mu) (Kan::Tn7) <i>λpir recA1 thi pro hsdR(γ-m⁺)</i>	(Simon et al., 1983)
BL21 (DE3)	F- ompT hsdSB (rB-mB-) gal dcm (DE3)	(Studier and Moffatt, 1986)
Plasmids used in this study		
pRDH10	<i>ori</i> (R6K) <i>mobRP4 sacRB Tet^R Cm^R</i>	(Kingsley et al., 1999)
pWSK29	<i>ori</i> (pSC101) Carb ^R	(Wang and Kushner, 1991)
pYDID	pWSK29 carrying <i>ydiD</i> gene transcribed from its native promoter	This study
pET28a	Expression vector with a His6-tag, Kan ^R	Novagen
pWJ19	pET28a carrying <i>hilD</i> gene transcribed from T7 promoter	This study
Critical Commercial Assays		
TRI-reagent	Molecular Research Center	cat#: RT 111
DNA-free kit	Applied Biosystems	cat#: AM1906
Aurum Total RNA kit	BioRad	cat#: 7326820
PowerSoil DNA Isolation Kit	Mo-Bio	cat#: 12888
Bradford assay	BioRad	cat#:5000006
Gel extraction kit	Qiagen	cat#: 28706
EMSA kit	Invitrogen	cat#: E33075
Lipocalin-2 ELISA	R&D systems	cat#: DY1857
Experimental Models: Cell Lines		
T84 colonic carcinoma cell	ATCC	cat#: CCL-248 RRID: CVCL_0555
Experimental Models: Organisms/Strains		
<i>Mus musculus</i> CBA/J	Jackson Labs	cat#: 000656 RRID: IMSD JAX: 000656
<i>Mus musculus</i> Gnotobiotic Swiss Webster	Bred in-house; originally acquired from Taconic	cat#: SW-F and SW-M

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Oligonucleotides		
Primers used in this study, see Table S1	This paper	N/A
Software and Algorithms		
Prims v7.0a	GraphPad	N/A

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript